Henry Meds Review: One Charge, and a Discount You Only Get Up Front

One payment a month, and what it is depends on the formulation. Compounded liraglutide, injected daily, is $179. Sublingual semaglutide is $179 for the 60 mg tier or $249 for the 180 mg tier. Weekly injected semaglutide is $297. Every one of those includes the provider visit, the medication, the injection supplies and ongoing support — Henry states there are no separate charges. All figures read off henrymeds.com/legal/programs on August 7, 2026.

Only if you pay for them up front, and Henry's own arithmetic shows it. Six months of liraglutide is listed at $1,074, which is exactly six months at $179 — no discount at all for committing. The saving appears only in the alternative: $894 paid in full, or $149 a month. Semaglutide behaves the same way: $1,782 for six months billed monthly, $1,482 if paid at once. Over a year the gap is larger — $3,564 versus $2,364, a $1,200 difference. So the question is not whether to commit; it is whether you can put $2,364 down before your first injection.

Month to month: liraglutide $2,148, sublingual semaglutide $2,148 at the 60 mg tier or $2,988 at 180 mg, and weekly injected semaglutide $3,564. Paid in full on day one: $1,428, $1,788 and $2,364 respectively. The cheapest honest year here is $1,428 for daily liraglutide — a real GLP-1, injected every day rather than weekly, which is the trade-off you are accepting for the price.

Yes, and Henry is unusually straight about them. Each price names its allowance in milligrams: $179 buys up to 90 mg of liraglutide every 60 days, or up to 60 mg of sublingual semaglutide; $249 buys up to 180 mg of the same sublingual tablets; $297 buys up to 10 mg of injectable semaglutide every 70 days, or 12.5 mg every 90. That transparency cuts both ways. It means you can check whether the dose you expect to reach fits inside the plan you are quoted — and it means the cheap tiers are cheap partly because they contain less drug.

Because Henry's page states two different things about it and we will not guess. The entry is headed "Tirzepatide Oral (3-Month Supply)" and priced at "$1,047 ($891 if paid in full)", but the description immediately beneath says the tablets are "delivered every 60 days for 6 months". If it is three months, that is $349 a month; if it is six, it is $174.50. Those are not close. The entry below it is worse — headed "Semaglutide Oral (3-Month Supply)" at $747, then described as tirzepatide tablets. Both were read on August 7, 2026. Ask Henry to confirm in writing before you buy either.

Cancelling is easy; escaping a term is not necessarily free. Henry's own answer: "You can cancel at any time in your account page of the patient portal… If you're on a multi-month plan, you may be required to pay out the rest of your balance unless you're unable to continue for medical-related reasons as determined by a healthcare provider." So the medical exit is protected and the change-of-mind exit may not be. Given that a monthly-billed six-month plan costs exactly the same per month as no plan at all, there is little reason to accept that exposure unless you are taking the paid-in-full discount.

Everywhere, including Washington, D.C. Henry does not publish a coverage map, so this comes from the state selector inside its own sign-up application, read on August 7, 2026: all fifty states plus the District of Columbia, with nothing missing. Two California caveats that are not exclusions: Henry warns that California patients may wait longer because of that state's extra compound testing requirements, and one sustained-release phentermine formulation is unavailable there. Separately, and applying everywhere, GLP-1 treatment is limited to patients aged 18 to 70.

Not in the telehealth GLP-1 enforcement waves. We checked all 113 letters across the September 2025, February 2026 and June 2026 rounds — the ones that named Zealthy, Ivim, Eden, Measured, Hims & Hers and dozens of others — and neither Adonis Health Inc. nor Henry Meds appears. That is a meaningful absence in a category where letters have been handed out freely, and it is worth stating precisely: it means FDA did not write to Henry about its website in those rounds. It is not evidence of a clean inspection record, because facility inspection findings are not published the same way.